Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Andrew Hill, David Hogg, Ivan Marquez-Rodas, Joel Jiang, Jasmine Rizzo, James Larkin, Jedd D Wolchok

Journal: The Lancet Oncology

Publisher: Elsevier BV

Citations are the number of DOI-registered works in Crossref that cite this paper; references are how many works it cites. Full text is on the publisher site via the DOI link.